Quick Answer
Niagen Bioscience, Inc. reported Operating Income of $16.28 million for fiscal year 2025.
Niagen Bioscience, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $16.28M | +110.7% |
| 2024 | $7.73M | +238.0% |
| 2023 | -$5.60M | +69.9% |
| 2022 | -$18.63M | +31.2% |
| 2021 | -$27.07M | -36.4% |
| 2020 | -$19.85M | +36.6% |
| 2019 | -$31.30M | +5.6% |
| 2018 | -$33.17M | -102.6% |
| 2017 | -$16.38M | -463.7% |
| 2016 | -$2.91M | -40.6% |
| 2015 | -$2.07M | +60.5% |
| 2014 | -$5.23M | -19.3% |
| 2013 | -$4.39M | +62.3% |
| 2012 | -$11.64M | -48.0% |
| 2011 | -$7.86M | -289.9% |
| 2010 | -$2.02M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.24M | +164.4% | +33.0% |
| June 30, 2025 | $3.19M | +1344.1% | -33.3% |
| March 31, 2025 | $4.77M | +752.8% | +197.9% |
| September 30, 2024 | $1.60M | +239.7% | +725.8% |
| June 30, 2024 | -$256.0K | +88.9% | +65.0% |
| March 31, 2024 | -$731.0K | +62.9% | +36.3% |
| September 30, 2023 | -$1.15M | +62.6% | +50.5% |
| June 30, 2023 | -$2.32M | +63.7% | -17.7% |
- Niagen Bioscience, Inc. showed an increase of +110.7% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Niagen Bioscience, Inc.’s operating income has grown by 907.0% (from -$2.02 million to $16.28 million).
- The most recent figure is from Niagen Bioscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: